

Naranie Shanmuganathan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/428750/publications.pdf>

Version: 2024-02-01

32
papers

600
citations

759055

12
h-index

642610

23
g-index

32
all docs

32
docs citations

32
times ranked

723
citing authors

#	ARTICLE	IF	CITATIONS
1	Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease. <i>Blood</i> , 2018, 132, 948-961.	0.6	152
2	Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells. <i>Leukemia</i> , 2018, 32, 2572-2579.	3.3	66
3	Successful treatment-free remission in chronic myeloid leukaemia and its association with reduced immune suppressors and increased natural killer cells. <i>British Journal of Haematology</i> , 2020, 191, 433-441.	1.2	52
4	Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemia. <i>Blood</i> , 2021, 137, 1196-1207.	0.6	48
5	Lineage of measurable residual disease in patients with chronic myeloid leukemia in treatment-free remission. <i>Leukemia</i> , 2020, 34, 1052-1061.	3.3	39
6	Clonal evolution and clinical implications of genetic abnormalities in blastic transformation of chronic myeloid leukaemia. <i>Nature Communications</i> , 2021, 12, 2833.	5.8	39
7	Aberrant RAG-mediated recombination contributes to multiple structural rearrangements in lymphoid blast crisis of chronic myeloid leukemia. <i>Leukemia</i> , 2020, 34, 2051-2063.	3.3	27
8	Molecular monitoring in CML: how deep? How often? How should it influence therapy?. <i>Hematology American Society of Hematology Education Program</i> , 2018, 2018, 168-176.	0.9	22
9	Modeling the safe minimum frequency of molecular monitoring for CML patients attempting treatment-free remission. <i>Blood</i> , 2019, 134, 85-89.	0.6	20
10	Safety, clinical effectiveness and trough plasma concentrations of intravenous posaconazole in patients with haematological malignancies and/or undergoing allogeneic haematopoietic stem cell transplantation: off-trial experience. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 3540-3547.	1.3	19
11	Treatment of chronic myeloid leukemia: assessing risk, monitoring response, and optimizing outcome. <i>Leukemia and Lymphoma</i> , 2017, 58, 2799-2810.	0.6	14
12	Asciminib: a new therapeutic option in chronic-phase CML with treatment failure. <i>Blood</i> , 2022, 139, 3474-3479.	0.6	14
13	Molecular monitoring in CML: how deep? How often? How should it influence therapy?. <i>Blood</i> , 2018, 132, 2125-2133.	0.6	11
14	The Hidden Pathogenesis of CML: Is BCR-ABL1 the First Event?. <i>Current Hematologic Malignancy Reports</i> , 2019, 14, 501-506.	1.2	11
15	The e13a2 BCR-ABL1 Transcript Is Associated with Higher Rates of Molecular Recurrence after Treatment-Free Remission Attempts: Retrospective Analysis of the Adelaide Cohort. <i>Blood</i> , 2018, 132, 1731-1731.	0.6	10
16	Epigenetic modifier gene mutations in chronic myeloid leukemia (CML) at diagnosis are associated with risk of relapse upon treatment discontinuation. <i>Blood Cancer Journal</i> , 2022, 12, 69.	2.8	10
17	Bone marrow fibrosis associated with long-term imatinib therapy: resolution after switching to a second-generation TKI. <i>Blood Advances</i> , 2019, 3, 370-374.	2.5	7
18	Asciminib for chronic myeloid leukaemia: Next questions. <i>British Journal of Haematology</i> , 2022, 199, 322-331.	1.2	7

#	ARTICLE	IF	CITATIONS
19	NGS in CML –New standard diagnostic procedure?. HemaSphere, 2019, 3, 48-50.	1.2	6
20	Combination of Nilotinib and Pegylated Interferon Alfa-2b Results in High Molecular Response Rates in Chronic Phase CML: Interim Results of the ALLG CML 11 Pinnacle Study. Blood, 2018, 132, 459-459.	0.6	6
21	Genomic Mechanisms Influencing Outcome in Chronic Myeloid Leukemia. Cancers, 2022, 14, 620.	1.7	6
22	Mutated Cancer-Related Genes Detected at Diagnosis of CML and a Novel Class of Variant Associated with the Philadelphia Translocation Are Both Independent Predictors of Inferior Outcomes. Blood, 2020, 136, 46-47.	0.6	4
23	Early Management of CML. Current Hematologic Malignancy Reports, 2019, 14, 480-491.	1.2	2
24	Multiplex technologies for the assessment of minimal residual disease and low-level mutation detection in leukaemia: mass spectrometry <i>versus</i> next-generation sequencing. British Journal of Haematology, 2022, 196, 19-30.	1.2	2
25	RNA-Based Targeted Gene Sequencing Improves the Diagnostic Yield of Mutant Detection in Chronic Myeloid Leukemia. Journal of Molecular Diagnostics, 2022, 24, 803-822.	1.2	2
26	Highly sensitive droplet digital polymerase chain reaction for <i><scp>BCR</scp> :: </i> <scp></i> <i>ABL1</i> messenger RNA </scp> identifies patients with chronic myeloid leukaemia with a low probability of achieving treatment-free remission. British Journal of Haematology, 0, , .	1.2	2
27	What's NEXT for CML-NGS mutation screening. Blood, 2020, 135, 515-516.	0.6	1
28	RNA Splicing Defects in Cancer-Linked Genes Indicate Mutation or Focal Gene Deletion and Are Associated with TKI Resistance in CML. Blood, 2019, 134, 662-662.	0.6	1
29	Predictors of Success in Treatment-Free Remission: A Single Centre Experience. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, S224.	0.2	0
30	Treatment-Free Remission in CML: Selecting the Best Candidates. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, S3-S5.	0.2	0
31	Response-Related Predictors of Survival and of Treatment-Free Remission in CML. Hematologic Malignancies, 2021, , 245-264.	0.2	0
32	An RNA-Based Next Generation Sequencing (NGS) Strategy Detects More Cancer Gene Mutations Than a DNA-Based Approach for the Prediction and Assessment of Resistance in CML. Blood, 2019, 134, 2918-2918.	0.6	0